Company intelligence / Profile preview
SN BioScience
Seongnam-si, Gyeonggi-do, South Koreasnbioscience.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
SNB-101 has shown promising results in preclinical and phase one clinical trials, demonstrating improved safety and efficacy compared to existing anticancer drugs. In a phase one study with 21 patients with various solid tumors, SNB-101 showed excellent safety and tolerability, with a disease control rate of 42.9% across all patients and 83.3% in the high dose group.
- Therapeutic areas
- OncologyEndocrinologyNeurology
- Modalities
- Small molecule drugsDrug conjugatesProtein drugsNanoparticlesNanoliposomesNano-micelles
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on SN BioScience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SN BioScience.